115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
住院 T2DM 患者从持续皮下胰岛素输注转换为基于 IDeg 方案的治疗：单中心回顾性分析
Authors Dong R, Gu L , Li H, Hu Y, Liu H, Kou X, Zhao Y, Zhao M, Shi B , Guo H, Qiang W
Received 15 August 2025
Accepted for publication 17 December 2025
Published 13 January 2026 Volume 2026:19 557994
DOI https://doi.org/10.2147/DMSO.S557994
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Halis Akturk
Ruiqing Dong,1,* Lifan Gu,2,* Heping Li,1 Yuanna Hu,3 Hui Liu,4 Xuna Kou,1 Yukun Zhao,1 Meng Zhao,1 Bingyin Shi,1 Hui Guo,1 Wei Qiang1
1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, People’s Republic of China; 2School of Future Technology, Xi’an Jiaotong University, Xi’an, 710049, People’s Republic of China; 3Department of Pain, The First Affiliated Hospital of Xinjiang Medical University, Urumqi City, 830017, People’s Republic of China; 4Biobank, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, People’s Republic of China
*These authors contributed equally to this article
Correspondence: Hui Guo, Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an, Shaanxi, 710061, People’s Republic of China, Tel/Fax +86-29-85323974, Email nfmguohui0709@xjtufh.edu.cn Wei Qiang, Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an, Shaanxi, 710061, People’s Republic of China, Tel/Fax +86-29-85323974, Email weiqiang@xjtufh.edu.cn
Background: Chinese patients with type 2 diabetes mellitus (T2DM) often initiate insulin therapy in the hospital, requiring rapid glycemic control and simplified post-discharge plans. Few clinical studies have focused on the transition protocols for continuous subcutaneous insulin infusion (CSII).
Objective: To evaluate the efficacy, safety, and patient satisfaction of transitioning from CSII to three treatment regimens: insulin degludec (IDeg), insulin degludec/insulin aspart (IDegAsp), or insulin degludec and liraglutide (IDegLira).
Methods: Clinical information and continuous glucose monitoring (CGM) data were retrospectively collected from 171 patients in a single center. Patient satisfaction and quality of life were assessed using standardized questionnaires in a three-month follow-up.
Results: After transition, mean glucose (MG) and glucose management indicator (GMI) decreased, while time in range (TIR) increased significantly. Coefficient of variation (CV) and time above range (TAR) decreased. Time below range (TBR) was unchanged in IDegAsp and IDegLira groups but slightly increased in the IDeg group (0.60% [0.00%, 1.60%] vs 1.10% [0.00%, 3.40%], P = 0.003). IDegAsp and IDegLira groups showed higher TIR and lower MG, GMI, CV, TAR, and TBR. 64.3% of IDegLira patients required one or fewer additional medications. Patient satisfaction was highest in the IDegLira group, with hypoglycemia avoidance, better weight management, fatigue prevention and less anxiety.
Conclusion: All three regimens enabled a smooth transition after CSII therapy. IDegAsp and IDegLira demonstrated superior glycemic control and reduced variability compared to IDeg. IDegLira was more convenient and associated with higher patient satisfaction.
Keywords: type 2 diabetes mellitus, insulin degludec, insulin degludec/insulin aspart, insulin degludec and liraglutide, continuous glucose monitoring
1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, People’s Republic of China; 2School of Future Technology, Xi’an Jiaotong University, Xi’an, 710049, People’s Republic of China; 3Department of Pain, The First Affiliated Hospital of Xinjiang Medical University, Urumqi City, 830017, People’s Republic of China; 4Biobank, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, People’s Republic of China
*These authors contributed equally to this article
Correspondence: Hui Guo, Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an, Shaanxi, 710061, People’s Republic of China, Tel/Fax +86-29-85323974, Email nfmguohui0709@xjtufh.edu.cn Wei Qiang, Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an, Shaanxi, 710061, People’s Republic of China, Tel/Fax +86-29-85323974, Email weiqiang@xjtufh.edu.cn
Background: Chinese patients with type 2 diabetes mellitus (T2DM) often initiate insulin therapy in the hospital, requiring rapid glycemic control and simplified post-discharge plans. Few clinical studies have focused on the transition protocols for continuous subcutaneous insulin infusion (CSII).
Objective: To evaluate the efficacy, safety, and patient satisfaction of transitioning from CSII to three treatment regimens: insulin degludec (IDeg), insulin degludec/insulin aspart (IDegAsp), or insulin degludec and liraglutide (IDegLira).
Methods: Clinical information and continuous glucose monitoring (CGM) data were retrospectively collected from 171 patients in a single center. Patient satisfaction and quality of life were assessed using standardized questionnaires in a three-month follow-up.
Results: After transition, mean glucose (MG) and glucose management indicator (GMI) decreased, while time in range (TIR) increased significantly. Coefficient of variation (CV) and time above range (TAR) decreased. Time below range (TBR) was unchanged in IDegAsp and IDegLira groups but slightly increased in the IDeg group (0.60% [0.00%, 1.60%] vs 1.10% [0.00%, 3.40%], P = 0.003). IDegAsp and IDegLira groups showed higher TIR and lower MG, GMI, CV, TAR, and TBR. 64.3% of IDegLira patients required one or fewer additional medications. Patient satisfaction was highest in the IDegLira group, with hypoglycemia avoidance, better weight management, fatigue prevention and less anxiety.
Conclusion: All three regimens enabled a smooth transition after CSII therapy. IDegAsp and IDegLira demonstrated superior glycemic control and reduced variability compared to IDeg. IDegLira was more convenient and associated with higher patient satisfaction.
Keywords: type 2 diabetes mellitus, insulin degludec, insulin degludec/insulin aspart, insulin degludec and liraglutide, continuous glucose monitoring